Precision Phenomics to Personalize Drug Therapy The promise of genomic medicine is the personalization of therapeutics based on one's genetic makeup. Current methods to identify genomic variation underlying adverse drug reactions (ADRs) and to predict drug effects progress slowly and lack disease-neutral approaches. In addition, the cost of new drug discovery is increasing rapidly, largely due to ADRs and efficacy failures. Thus, repurposing old drugs for new indications offer advantages of both safety and reduced development costs. We will develop and apply phenome-wide, medication-wide approaches to dense, longitudinal Electronic Health Record (EHR) data linked to DNA to discover genetic variants associated with ADRs, predict new indications for drugs, and identify new phenotype associations for genetic variants known to impact drug response.
In Specific Aim 1, we will genotype 30,000 individuals on a genome-wide array enriched with variants underlying cardiac electrical activity, drug metabolism, HLA variants, and drug targets. Combining these data with the extant genotypes in our institutional biobank BioVU will result in population of 66,000 individuals with dense genome-wide genotype data. We will perform phenome-wide associations studies (PheWAS, a methodology we have developed) for genes and variants identified in Projects 1 and 2 and known pharmacovariants.
In Specific Aim 2, we will use phenome-wide approaches to repurpose existing medications and predict side effects. Building on methods that successfully replicated known apremilast (PDE4 inhibitor used for autoimmune disease) indications and suggested new, biologically plausible repurposing in other diseases, we will perform PheWAS on drug targets for nearly all currently used medications as a tool to identify new disease indications and side effects. Existing indications will serve as anchors to orient results toward new efficacies and possible side effects. Then, we will prioritize new indications for further analysis using network analysis and systematic evidence reviews.
In Specific Aim 3, we will use natural language processing and coded EHR data to identify ADRs from EHR data. Specific ADRs assessed will include diseases, laboratory abnormalities, cutaneous hypersensitivity reactions, and electrocardiographic traits. Our methods will extract both provider-identified ADRs as well as find known clinical events documented but not explicitly recorded as an ADR. Then, we will discover genetic variants predicting the ADRs. In both Specific Aims 2 and 3, we will replicate prioritized novel associations in external EHR-linked biobanks and using candidate gene sequencing or specific HLA 4-digit typing of validated phenotypes. The results of this study will be to dramatically increase the catalog of genetic predictors of drug response and to create a library of potential repurposing for nearly all medications.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Specialized Center (P50)
Project #
5P50GM115305-04
Application #
9300960
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Galligan, James J; Wepy, James A; Streeter, Matthew D et al. (2018) Methylglyoxal-derived posttranslational arginine modifications are abundant histone marks. Proc Natl Acad Sci U S A 115:9228-9233
Trubiano, Jason A; Grayson, M Lindsay; Phillips, Elizabeth J et al. (2018) Antibiotic allergy testing improves antibiotic appropriateness in patients with cancer. J Antimicrob Chemother 73:3209-3211
Roden, Dan M; Van Driest, Sara L; Wells, Quinn S et al. (2018) Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation. Circ Res 122:1176-1190
Gamazon, Eric R; Segrè, Ayellet V; van de Bunt, Martijn et al. (2018) Using an atlas of gene regulation across 44 human tissues to inform complex disease- and trait-associated variation. Nat Genet 50:956-967
Phillips, Elizabeth J; Sukasem, Chonlaphat; Whirl-Carrillo, Michelle et al. (2018) Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther 103:574-581
da Silva Antunes, Ricardo; Paul, Sinu; Sidney, John et al. (2018) Correction: Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses. PLoS One 13:e0193382
Derrick, Michael Ian; Williams, Kristina Blis; Shade, Lincoln Morris Payne et al. (2018) A survey of drug allergy training opportunities in the United States. J Allergy Clin Immunol Pract 6:302-304
Mosley, Jonathan D; Feng, QiPing; Wells, Quinn S et al. (2018) A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers. Nat Commun 9:3522
Phillips, Elizabeth J; Mallal, Simon A (2018) Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration. J Clin Invest 128:2746-2749
White, Katie D; Abe, Riichiro; Ardern-Jones, Michael et al. (2018) SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. J Allergy Clin Immunol Pract 6:38-69

Showing the most recent 10 out of 114 publications